The activity of clarithromycin alone and in combination with other antimycobacterial agents was evaluated in the beige (C57BV6J bg'/bg') mouse model of disseminated Mycobacterium avium complex (MAC) infection. A dose-response experiment was performed with clarithromycin at 50, 100, 200, or (4, 7, 10, 18) . The activities of clarithromycin in MAC-infected macrophage cultures (19, 27) and murine models of disseminated MAC infection (4, 12) have been demonstrated previously. After a single oral dose of 50 mg/kg of body weight in C57BL/6J mice, CILA achieves a peak level in serum of 2.6 ,ug/ml (4). After administration of 400 or 1,200 mg of CLA orally in humans, peak levels in serum are 2.1 tag/ml (15) and 4.4 ,ug/ml (22), respectively.
Preliminary results of CLA-containing regimens in the treatment of disseminated MAC infection in persons with AIDS are encouraging (2, 3, 21) . The purpose of the present study was to evaluate the activity of CILA alone and in combination with various antimycobacterial agents against several MAC isolates in the beige mouse model of disseminated MAC infection.
MATERIALS AND METHODS
Drugs. CILA and temafloxacin (TEM) were provided by Abbott Laboratories, Abbott Park, Ill. Clofazimine (CFZ) was provided by CIBA-GEIGY Pharmaceuticals, Summit, N.J. Rifabutin (RBT) was provided by Adria Laboratories, Dublin, Ohio. Amikacin (AMK), ethambutol (EMB), and rifampin (RIF) were obtained from Sigma Chemical Co., St. Louis, Mo.
CLA and TEM were dissolved in absolute ethanol, with subsequent dilution in distilled water prior to administration. CFZ, RIF, and RBT were dissolved in dimethyl sulfoxide, with A cell suspension with a predominantly (>95%) transparent colony morphology was used for infection. Isolates were passaged through beige mice every 3 months to maintain virulence.
Media. The organisms were grown in modified Middlebrook 7H10 broth with 10% Middlebrook OADC enrichment and 0.05% Tween 80 (25) There were five mice per group, unless otherwise noted.
In each experiment, a control group of infected but untreated mice (late controls) was compared with treated groups of mice at the completion of the treatment period. In three of the combination studies, an additional group of control mice (early controls) was sacrificed at the initiation of therapy. Treatment was started 7 days after infection, and treatment was given daily for 10 days unless otherwise noted. All drugs except AMK and TEM were given orally by gavage; AMK and TEM were administered subcutaneously. Animals were sacrificed by cervical dislocation 2 days after the last dose of drug. Selected organs (spleens; spleens and lungs; or spleens, livers, and lungs) were aseptically removed and ground in a tissue homogenizer. The number of viable organisms was determined by titration on 7H10 agar plates.
Statistical evaluation. The viable cell counts were converted to logarithms, which were then evaluated with one-or two-variable analyses of variance. Statistically significant effects from the analyses of variance were further evaluated by the Tukey honestly significant difference tests (14) to make pairwise comparisons among means. The results of the statistical evaluation for the organs are summarized below.
RESULTS
CILA dose-response study. CLA at 50, 100, 200, or 300 mg/kg of body weight was given daily to female mice which had been infected with 1.4 x 107 viable M. avium ATCC 49601 (Fig. 1 ). CLA at all doses reduced organ cell counts compared with those in mice given no treatment (P < 0.01). Treatment at 100 mg/kg reduced cell counts in spleens and livers compared with the counts in the group treated with 50 mg/kg (P < 0.01). An increase in cell counts in the lungs of the group treated with 100 mg/kg compared with that in the lungs of the group treated with 50 mg/kg was noted (P < 0.05). Treatment with 200 mg/kg reduced the cell counts in spleens and livers compared with the counts in the spleens and livers of the group treated with 100 mg/kg (P < 0.01). A reduction in cell counts in lungs in the group treated with 200 mg/kg compared with that in the lungs of the group treated with 100 mg/kg was significant (P < 0.01). The difference in cell counts in the lungs of the group treated with 200 mg/kg compared with that in the lungs of the group treated with 50 mg/kg was not significant (P > 0.05). The difference in cell counts between mice treated with 200 and 300 mg/kg was not significant for any organ (P > 0.05).
Extended duration of therapy. CILA at 200 mg/kg was given daily to female mice which had been infected with 1.1 x 107 viable M. avium ATCC 49601. Mice received treatment for 10 or 20 days. Untreated control groups were sacrificed at the completion of each treatment period. The increase in cell counts between the control groups that received treatment for 10 and 20 days was significant for livers and lungs (P < 0.01) but not spleens (P > 0.05) (Fig. 2) . Treatment with CLA reduced cell counts in organs at each time point compared with the counts in mice given no treatment (P < 0.01). Treatment for 20 days further reduced cell counts in each organ compared with the counts in mice treated for 10 days (P < 0.01). Treatment with CLA for 10 days reduced cell counts of each isolate in spleens compared with those in the spleens of mice given no treatment (P < 0.01) (Fig. 3) .
Combination of CIA with AMK, EMB, RIlF, or CFZ. CLA (200 mg/kg) was given daily alone or in combination with AMK (100 mg/kg), EMB (125 mg/kg), RIF (20 mg/kg), or CFZ (20 mg/kg) to male mice which had been infected with 3.3 x 107 viable M. avium ATCC 49601. A group of early control mice was sacrificed 7 days after infection. The increase in cell counts between early and late control groups was significant for spleens and lungs (P < 0.01) (Fig. 4) . Treatment with CILA alone and all combinations reduced cell counts in spleens and lungs compared with those in the spleen and lungs of the early and late control groups (P < 0.01).
The difference in cell counts between mice treated with CILA alone and those treated with CLA-AMK or CLA-EMB was not significant for organisms in spleens or lungs (P > 0.05). CLA alone was more active than the combination of CLA-RIF (P < 0.05 for organisms in spleens; P < 0.01 for organisms in lungs). The combination of CLA-CFZ was more active than CLA alone against organisms in spleens and lungs (P < 0.01).
Combination of CLA with TEM or RBT. CLA (200 mg/kg) was given daily alone or in combination with TEM (100 mg/kg) or RBT (20 mg/kg) to female mice which had been infected with 1.9 x 107 viable M. avium ATCC 49601. A separate group received daily TEM alone at 100 mg/kg. A group of early control mice was sacrificed 7 days after infection. The difference in cell counts between early and late control groups was significant only for lungs (P < 0.01) (Fig. 5) .
Treatment with CILA alone reduced cell counts in spleens and lungs compared with the counts in the spleens and lungs of mice in the early and late control groups (P < 0.01). Treatment with TEM alone did not reduce cell counts in spleens compared with the counts in the spleens of mice in the early or late control groups (P > 0.05). Treatment with TEM alone reduced cell counts in lungs compared with the counts in the lungs of late controls (P < 0.01) but not in those of early controls.
CIA alone was more active than the combination of CLA-TEM (P < 0.01 for organisms in spleens; P < 0.05 for organisms in lungs). The combination of CILA-RBT was more active than CILA alone against organisms in spleens and lungs (P < 0.01).
Combination therapy against MAC isolate 1408-3. CLA (200 mg/kg) was given daily alone or in combination to female mice which had been infected with 6.2 x 106 viable MAC isolate 1408-3. Combination groups received either one or two additional agents, as follows: RIF (20 mg/kg), EMB (125 mg/kg), CFZ (20 mg/kg), RIF and EMB, RIF and CFZ, or CFZ and EMB. A group of early control mice was sacrificed 7 days after infection. The difference in cell counts between early and late control groups was not significant for organisms in spleens (P > 0.05) (Fig. 6) .
The reductions in cell counts seen with CIA alone and all combinations were significant compared with the reductions in the early and late control groups (P < 0.01). CLA alone was as active as the combinations of CLA-RIF, CLA-EMB, and CILA-RIF-EMB (P > 0.05). The CFZ, CLA-RIF-CFZ or CLA-CFZ-EMB) wi compared with the reductions after treatme alone (P < 0.01). The differences in cell coui three CFZ-containing regimens were not sig 0.05). DISCUSSION CLA at 200 mg/kg had activity against four tested in vivo. The reduction in log CFUs in sp the late control and the CLA-treated group treatment experiment ranged from 0.8 (MAC which the MIC was 1 ,g/ml) to 2.1 (M. avium for which the MIC was 4 ,g/ml). There was lit between in vitro MICs determined by the method and the activity of CILA in the mouse In order to examine the interexperimenta CILA activity against a single MAC isolate (M. 49601), we reviewed seven separate studies (fo the current report; the others are not give reduction in log CFUs in spleens between th and CLA (200 mg/kg)-treated groups occurred narrow range (from 1.6 to 2.1; mean, 1.9). (range, 1.1 x 107 to 3.3 x 107 viable organ appear to correlate with activity in vivo. Sinr gender did not appear to influence CLA activi particular isolate. Drug preparation and admin performed by the same investigator in a simil each experiment.
Previous studies of promising new agents mouse have often been limited by the use of isolate (6, 16). Unlike wild-type strains of M. MAC isolates have considerable variation in in tibility (9, 11, 26) . Parallel testing of additioi vitro and in vivo may help to determine whethe can be used to predict activity in the mouse n The rationale for combination chemotherap ment of mycobacterial infections is based on n emergence of drug resistance and, possibly, i activity of agents which have only modest used alone. Although the current studies do n( question of emergence 
